Nat Rev Drug Discov. 2012 Mar 1;11(3):185-6. doi: 10.1038/nrd3675.
In November 2011, tafamidis (Vyndaqel; Pfizer), a small molecule that inhibits the dissociation of transthyretin tetramers, was granted marketing authorization by the European Commission for the treatment of transthyretin amyloidosis in adult patients with stage 1 symptomatic polyneuropathy to delay peripheral neurological impairment.
2011 年 11 月，欧盟委员会批准塔法米迪司（Vyndaqel；辉瑞）上市，这是一种小分子药物，可抑制转甲状腺素蛋白四聚体的解离，用于治疗有症状的一期多发性神经病的成年转甲状腺素蛋白淀粉样变性患者，以延缓周围神经损伤。
